Literature DB >> 10867834

Effects of macrolides on interleukin-8 secretion from human nasal epithelial cells.

K Fujita1, T Shimizu, Y Majima, Y Sakakura.   

Abstract

Low-dose, long-term macrolide treatment has recently been reported to be very effective in patients with chronic airway diseases. We examined the in vivo and in vitro effects of 14-membered macrolide antibiotics erythromycin (EM) and clarithromycin (CAM) on interleukin (IL)-8 secretion from human nasal epithelial cells. Fifteen patients with chronic sinusitis received macrolide treatment (CAM 400 mg/day) for 1 to 3 months. The number of infiltrated neutrophils and IL-8 concentrations in the nasal discharges of these patients decreased significantly at 1 to 2 months after the treatment. In vitro effects of EM and CAM on IL-8 secretion were examined in nasal epithelial cells cultured at the air-liquid interface. After 14-day culture in the air-liquid interface, macrolide antibiotics were added in medium for 24 h. EM and CAM at concentrations of 10(-4) M did not affect spontaneous secretions or IL-1 beta-induced secretions of IL-8 either apically or basolaterally. When cells were preincubated with 10(-4) M CAM for 7 days, the IL-1 beta-induced secretion of IL-8 decreased significantly. However, no difference was observed between the effects of 10(-4) M CAM and 10(-4) M josamycin, a 16-membered macrolide. These results suggest that macrolide treatment inhibits neutrophil infiltration and IL-8 secretion in nasal epithelium in vivo and that these clinical effects depend on a mechanism other than the direct action of macrolide on nasal epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867834     DOI: 10.1007/s004050050222

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  6 in total

1.  Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes.

Authors:  Tatsuya Tsuda; Chika Ishikawa; Hiroe Konishi; Yoshiaki Hayashi; Noboru Nakagawa; Masato Matsuki; Hitoshi Mizutani; Kiyofumi Yamanishi
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

Review 2.  Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin.

Authors:  André G Buret
Journal:  Can J Vet Res       Date:  2010-01       Impact factor: 1.310

3.  Clarithromycin in the Management of Chronic Rhinosinusitis: Preliminary Results of a Possible Its New Use.

Authors:  F Sireci; R Speciale; S Gallina; R Sorrentino; F R Canevari
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-07-20

4.  The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial.

Authors:  Jodie L Simpson; Heather Powell; Katherine J Baines; David Milne; Harvey O Coxson; Philip M Hansbro; Peter G Gibson
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

5.  Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients.

Authors:  Mandy Menzel; Hamid Akbarshahi; Leif Bjermer; Lena Uller
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

6.  Azithromycin inhibits mucus hypersecretion from airway epithelial cells.

Authors:  Takeshi Shimizu; Shino Shimizu
Journal:  Mediators Inflamm       Date:  2012-04-23       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.